Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | NAAA | Q02083 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TERT | O14746 | 1/20 | 0.41 |
| ▸ | GLS | O94925 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15618133 | 1.00 | NPC1 (0.51) | NPC1LMNATP53HPGDRAB9A | |
| SCHEMBL6958262 | 1.00 | NPC1 (0.51) | NPC1LMNATP53HPGDRAB9A | |
| SCHEMBL13340721 | 0.89 | NAAA (0.49) | NPC1LMNATP53HPGDRAB9A | |
| SCHEMBL20576754 | 0.86 | NAAA (0.53) | NPC1LMNATP53HPGDRAB9A | |
| SCHEMBL20576756 | 0.86 | NAAA (0.53) | NPC1LMNATP53HPGDRAB9A | |
| SCHEMBL15577902 | 0.85 | NPC1 (0.51) | NPC1LMNATP53HPGDRAB9A | |
| SCHEMBL18007116 | 0.85 | NAAA (0.57) | NPC1LMNATP53HPGDRAB9A | |
| SCHEMBL15577903 | 0.85 | NPC1 (0.51) | NPC1LMNATP53HPGDRAB9A | |
| SCHEMBL19810282 | 0.85 | NAAA (0.57) | NPC1LMNATP53HPGDRAB9A | |
| SCHEMBL4426198 | 0.85 | NPC1 (0.51) | NPC1LMNATP53HPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374536-A1 | GENETICALLY MODIFIED SEED COMBINED WITH SPORE FORMING BACTERIUM AND OPTIONAL INSECT CONTROL AGENTS AND METHODS FOR TREATING PLANTS | BASF CORPORATION (US) | 2023-11-23 | — | — | US | claimed |
| US-6340751-B1 | REACTION OF IMIDAZOLONE WITH AMIDE AND MAGNESIUM COMPOUND | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2002-01-22 | — | — | US | claimed |
| EP-3723819-B1 | WOUND DRESSING | ANIMAL ETHICS PTY LTD (AU) | 2026-04-22 | — | — | EP | disclosed |
| US-12599141-B2 | Rod-shaped plant viral nanoparticles or virus-like particles for agricultural applications | CASE WESTERN RESERVE UNIVERSITY (US) | 2026-04-14 | — | — | US | disclosed |
| US-20260033478-A1 | MATERIALS AND METHODS FOR THE CONTROL OF NEMATODES | LOCUS SOLUTIONS IPCO LLC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12465041-B2 | Materials and methods for the control of nematodes | LOCUS SOLUTIONS IPCO, LLC (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250268856-A1 | Pain Relieving Method | ANIMAL ETHICS PTY LTD (AU) | 2025-08-28 | — | — | US | disclosed |
| EP-3976018-B1 | COMPOSITION FOR USE IN THE TREATMENT OF FOOT AND MOUTH DISEASE (FMD), SCABBY MOUTH (ORF), PICORNAVIRUS, PARAPOXVIRUS, AND A PATHOGENIC DISEASE CAUSING POX LESIONS | ANIMAL ETHICS PTY LTD (AU) | 2024-08-28 | — | — | EP | disclosed |
| US-20240091150-A1 | PHARMACEUTICAL COMPOSITION COMPRISING, AS THICKENING AGENT, A COMPOSITION HAVING POLAR MEDIA THICKENING PROPERTIES | SOC DEXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES SEPPIC (FR) | 2024-03-21 | — | — | US | disclosed |
| US-20240057581-A1 | MATERIALS AND METHODS FOR THE CONTROL OF NEMATODES | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2024-02-22 | — | — | US | disclosed |
| US-11879467-B1 | Fog generator | DUNKLAU DANA P (US) | 2024-01-23 | — | — | US | disclosed |
| EP-2889287-B1 | DOLASTATIN-10 DERIVATIVE, METHOD OF PRODUCING SAME AND ANTICANCER DRUG COMPOSITION CONTAINING SAME | CELLTRION INC (KR) | 2016-08-31 | — | — | EP | disclosed |
| US-9278996-B2 | Dolastatin-10 derivative, method of producing the same and anticancer drug composition containing the same | CELLTRION, INC. (KR) | 2016-03-08 | — | — | US | disclosed |
| US-20150225455-A1 | DOLASTATIN-10 DERIVATIVE, METHOD OF PRODUCING THE SAME AND ANTICANCER DRUG COMPOSITION CONTAINING THE SAME | CELLTRION, INC. (KR) | 2015-08-13 | — | — | US | disclosed |
| EP-2889287-A1 | DOLASTATIN-10 DERIVATIVE, METHOD OF PRODUCING SAME AND ANTICANCER DRUG COMPOSITION CONTAINING SAME | Celltrion, Inc. (KR) | 2015-07-01 | — | — | EP | disclosed |
| WO-2015087351-A2 | PROCESS FOR THE PREPARATION OF (1S,3S,7S,10R,11S,12S,16R)-7,11-DIHYDROXY-8,8,10,12,16-PENTAMETHYL-3-[(1E)-1-METHYL-2-(2-METHYL-4-THIAZOLYL)ETHENYL]-17-OXA-4-AZABICYCLO[14.1.0]HEPTADECANE-5,9-DIONE AND INTERMEDIATES THEREOF | MSN LABORATORIES PRIVATE LIMITED (IN) | 2015-06-18 | — | — | WO | disclosed |
| WO-2014046441-A1 | DOLASTATIN-10 DERIVATIVE, METHOD OF PRODUCING SAME AND ANTICANCER DRUG COMPOSITION CONTAINING SAME | (주)셀트리온 (KR) | 2014-03-27 | — | — | WO | disclosed |
| EP-0974582-B1 | Process for the preparation of 4-substituted azetidinone derivatives | TAKASAGO PERFUMERY CO LTD (JP) | 2003-02-12 | — | — | EP | disclosed |
| US-6340751-B1 | REACTION OF IMIDAZOLONE WITH AMIDE AND MAGNESIUM COMPOUND | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2002-01-22 | — | — | US | disclosed |
| EP-0974582-A1 | Process for the preparation of 4-substituted azetidinone derivatives | Takasago International Corporation (JP) | 2000-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225455-A1 | DOLASTATIN-10 DERIVATIVE, METHOD OF PRODUCING THE SAME AND ANTICANCER DRUG COMPOSITION CONTAINING THE SAME | DAD1, DDOST, SCD5 | NPC1 33/4885LMNA 783/4885TP53 967/4885 |
| US-20230374536-A1 | GENETICALLY MODIFIED SEED COMBINED WITH SPORE FORMING BACTERIUM AND OPTIONAL INSECT CONTROL AGENTS AND METHODS FOR TREATING PLANTS | GMNN, GMDS, DBF4 | NPC1 4164/4885LMNA 2954/4885TP53 3446/4885 |
| US-20260033478-A1 | MATERIALS AND METHODS FOR THE CONTROL OF NEMATODES | MGLL, DAGLA, SGMS2 | NPC1 410/4885LMNA 1981/4885TP53 3882/4885 |
| US-20240091150-A1 | PHARMACEUTICAL COMPOSITION COMPRISING, AS THICKENING AGENT, A COMPOSITION HAVING POLAR MEDIA THICKENING PROPERTIES | PHOSPHO1, GYPA, SGTA | NPC1 4746/4885LMNA 1281/4885TP53 3106/4885 |
| US-12599141-B2 | Rod-shaped plant viral nanoparticles or virus-like particles for agricultural applications | PRNP, PCNP, VIM | NPC1 4344/4885LMNA 273/4885TP53 1501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.